Drug firm Zydus Cadila has received tentative nod from the US health regulator to market Clofarabine injection, used for treatment of cancer of the white blood cells, in the American market.
Cadila Healthcare officially stated that stated, “Zydus Cadila has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Clofarabine injection 20mg/20ml vials.”
The group now has more than 100 approvals and has filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in fiscal 2003-04, it added.
Clofarabine is used to treat acute lymphoblastic leukemia (a type of cancer of the white blood cells) of 1-21 years old pediatric patients. Cadila Healthcare stock closed 2.56 per cent up at Rs 344.10 on BSE.
